152 related articles for article (PubMed ID: 8496430)
1. Local tolerability of topically applied methylprednisolone aceponate.
Kecskés A; Jahn P; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
[No Abstract] [Full Text] [Related]
2. Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers.
Kecskés A; Jahn P; Matthes H; Kuhlmann RK; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):789-92. PubMed ID: 8496431
[No Abstract] [Full Text] [Related]
3. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
4. Side effects of topical glucocorticoids.
Mills CM; Marks R
Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
[No Abstract] [Full Text] [Related]
5. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
Korting HC
Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
[No Abstract] [Full Text] [Related]
6. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
[TBL] [Abstract][Full Text] [Related]
7. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
8. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
[TBL] [Abstract][Full Text] [Related]
9. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
Korting HC
Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
[No Abstract] [Full Text] [Related]
10. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
Szadurski J; Renz F; Gasser D
Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers.
Kecskés A; Jahn P; Wendt H; Lange L; Kuhlmann RK
Eur J Clin Pharmacol; 1992; 43(2):157-9. PubMed ID: 1425873
[TBL] [Abstract][Full Text] [Related]
12. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.
Kecskés A; Jahn P; Wendt H; Kleine-Kuhlmann R; Lange L
Arzneimittelforschung; 1993 Feb; 43(2):144-7. PubMed ID: 8457237
[TBL] [Abstract][Full Text] [Related]
13. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
Marks R
Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
[TBL] [Abstract][Full Text] [Related]
14. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
15. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study.
Mercader-García P; Pastor-Nieto MA; García-Doval I; Giménez-Arnau A; González-Pérez R; Fernández-Redondo V; Serra-Baldrich E; Cordoba-Guijarro S; Gatica-Ortega ME; Silvestre-Salvador JF;
Contact Dermatitis; 2018 Jan; 78(1):76-82. PubMed ID: 28960334
[TBL] [Abstract][Full Text] [Related]
16. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules.
Fukaya Y; Masutani M; Koyama Y; Takahashi H; Ueda H
J Dermatol; 1990 Jan; 17(1):28-33. PubMed ID: 2329214
[TBL] [Abstract][Full Text] [Related]
17. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
18. Steroids in dermatology.
Miller JA; Levene GM
Br J Hosp Med; 1982 Oct; 28(4):331-2, 337-8. PubMed ID: 6291678
[No Abstract] [Full Text] [Related]
19. The chamber vasoconstrictor assay. I. Comparison with occluded and unoccluded tests using four corticosteroids.
Somerma S
Clin Exp Dermatol; 1980 Jun; 5(2):191-6. PubMed ID: 7438514
[No Abstract] [Full Text] [Related]
20. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
Callender VD; Young CM; Haverstock CL; Carroll CL; Feldman SR
Cutis; 2005 Jun; 75(6):317-21. PubMed ID: 16047868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
